NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.19 +0.24 (+0.30%) GOLD FUTURES
2,312.70 +3.10 (+0.13%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,258.41 +1,095.70 (+2.37%)
Nuvation Bio Inc. (NUVB)
After hours:
| Previous close | 3.2000 |
| Open | 3.2800 |
| Bid | 3.2700 x 4000 |
| Ask | 3.3100 x 4000 |
| Day's range | 3.1500 - 3.3050 |
| 52-week range | 0.9500 - 4.1600 |
| Volume | |
| Avg. volume | 1,401,526 |
| Market cap | 806.804M |
| Beta (5Y monthly) | 1.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NEW YORK, April 24, 2024--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that updated data from the Phase 2 TRUST-I clinical study (NCT04395677) evaluating taletrectinib in patients in China with ROS1-positive non-small cell lung cancer (NSCLC) will be reported in an oral presentation at the 2024 American Society of Clinical Oncology
- Business Wire
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
NEW YORK, April 10, 2024--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the completion of the acquisition of AnHeart Therapeutics Ltd. (AnHeart), a late-stage, global biopharmaceutical company developing novel precision therapies for people with cancer. With the acquisition’s completion, AnHeart is now a wholly-owned subsidiary of N
- Business Wire
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
NEW YORK, March 28, 2024--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company’s commercial strategy and operations, including marketing, sales, and market access.
